Sheldon is set to join GSK after nearly two decades at AstraZeneca, the people said, asking not to be identified because the information is private.
He started at AstraZeneca as a research scientist and eventually became global head of business development and licensing for oncology research and development, working on acquisitions and partnerships in this key area, his LinkedIn profile shows. Last year, Sheldon moved into a new ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.